Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Inspiratory Muscle Training Plus Cold Water Immersion After Muscle-Damaging Exercise

3 novembre 2026 mis à jour par: Mete Berk Demiryol, University of Gaziantep

The Combined Effect of Cold Water Immersion and Inspiratory Muscle Training on the Recovery From Exercise-Induced Muscle Damage and Physical Performance: A Randomized, Placebo-Controlled Crossover Study

The purpose of this study is to examine, using a placebo-controlled design, the additional effect of inspiratory muscle training (IMT) added to cold water immersion (CWI) on recovery and muscle performance following exercise-induced muscle damage (EIMD), and to determine whether this effect varies depending on the timing of the intervention. The study will include 12 healthy male athletes aged 18-22 who have been licensed for at least 4 years and are actively involved in sports. Each participant will undergo four different interventions in a randomized order determined by the Williams balanced sequence following muscle damage induced by eccentric exercise on an isokinetic dynamometer: CWI + placebo IMT immediately after exercise, IMT + CWI immediately after exercise, IMT + CWI 24 hours after exercise, and a control condition with no recovery intervention. The sessions will be conducted in weekly cycles with 7-day intervals, alternating between the dominant and non-dominant legs; thus, there will be a 14-day interval between two loading sessions for the same leg. All measurements will be taken during the week. Muscle strength will be assessed using an isokinetic dynamometer; markers of muscle damage (CK, myoglobin, LDH) will be measured via blood samples; and muscle pain will be evaluated using the Visual Analog Scale (VAS) before each exercise session and 48 hours after exercise.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

12

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Şehitkamil
      • Gaziantep, Şehitkamil, Turquie (Türkiye)
        • Gaziantep University, Faculty of Sports Sciences, Sports Performance and Testing Laboratory

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 22 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

  • Be a male between the ages of 18 and 22
  • Hold a sports license valid for at least 4 years
  • Be actively involved in sports
  • Not smoke or use similar substances

Exclusion Criteria:

  • Having sustained a sports injury within the past 2 years
  • Having engaged in exercise that could cause muscle damage within the past 15 days
  • Cold intolerance, cold urticaria, or Raynaud's phenomenon
  • Known cardiovascular, respiratory, or musculoskeletal disease
  • Use of anti-inflammatory medication or dietary supplements that could affect recovery during the study period

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur factice: CWI + placebo IMT

Device: Placebo IMT - 2 × 30 breaths at 15% of MIP using POWERbreathe (1 min between sets), immediately following the short test after EIMD. Other: Immersion in cold water - immediately following the placebo IMT, in 10-12 °C water, up to waist level or with legs fully submerged, for 10-15 minutes.

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Same device, position and volume as inspiratory muscle training (two sets of 30 breaths, 1 minute rest), but at 15% of maximal inspiratory pressure, a load considered below the training threshold. Followed immediately by cold water immersion.

Expérimental: IMT + CWI (immediately)

Other: Inspiratory muscle training + cold water immersion. Immediately following the short test after EIMD, 2 × 30 breaths at 40% of MIP using POWERbreathe (1 min rest between sets), followed by CWI.

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Two sets of 30 breaths at 40% of maximal inspiratory pressure with 1 minute rest between sets, using a POWERbreathe device; oxygen saturation is monitored by pulse oximetry. Followed immediately by cold water immersion.

Expérimental: IMT + CWI (at 24 hours)

Other: Inspiratory muscle training + cold water immersion. The same IMT and CWI protocol is administered 24 hours after EIMD; the 48-hour measurement is taken relative to EIMD (24 hours after the intervention).

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Two sets of 30 breaths at 40% of maximal inspiratory pressure with 1 minute rest between sets, using a POWERbreathe device; oxygen saturation is monitored by pulse oximetry. Followed immediately by cold water immersion.

Aucune intervention: Control

No recovery procedure is performed after the EIMD protocol; only measurements are taken.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Peak Power ( 60°/s)
Délai: The 48-hour period before and after EIMD in each phase

Highest torque (Nm) measured during a 5-rep maximum test on an isokinetic dynamometer

The 48-hour period before and after EIMD in each phase
Peak Power ( 180°/s)
Délai: The 48-hour period before and after EIMD in each phase

Highest torque (Nm) measured during a 10-rep maximum test on an isokinetic dynamometer

The 48-hour period before and after EIMD in each phase
Average Power ( 180°/s- 60°/s)
Délai: The 48-hour period before and after EIMD in each phase

Average of peak torque values during test repetitions (Nm)

The 48-hour period before and after EIMD in each phase
Serum creatine kinase (CK)
Délai: The 48-hour period before and after EIMD in each phase

CK level in venous blood (U/L)

The 48-hour period before and after EIMD in each phase
Myoglobin (Mb)
Délai: The 48-hour period before and after EIMD in each phase

Myoglobin level in venous blood (ng/mL)

The 48-hour period before and after EIMD in each phase
Lactate dehydrogenase (LDH)
Délai: The 48-hour period before and after EIMD in each phase

LDH level in venous blood (U/L)

The 48-hour period before and after EIMD in each phase

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
H/Q ratio
Délai: The 48-hour period before and after EIMD in each phase

Hamstring-to-quadriceps peak torque ratio (60°/s and 180°/s)

The 48-hour period before and after EIMD in each phase
VAS
Délai: During each period: before EIMD, immediately after EIMD, and 48 hours after EIMD

0-10 cm Visual Analog Scale (0 = no pain, 10 = very severe pain)

During each period: before EIMD, immediately after EIMD, and 48 hours after EIMD
Fatique Index
Délai: The 48-hour period before and after EIMD in each phase

Fatigue index (%) calculated from a test consisting of 10 cycles at 180°/s

The 48-hour period before and after EIMD in each phase

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

31 décembre 2026

Achèvement de l'étude (Estimé)

31 décembre 2026

Dates d'inscription aux études

Première soumission

27 octobre 2026

Première soumission répondant aux critères de contrôle qualité

3 novembre 2026

Première publication (Réel)

9 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2026/9504

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

"Individual participant data will not be shared for privacy reasons; aggregate results will be published."

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner